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Abstract
Since 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease
(YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks
of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990–2002,
we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting
rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19–29 years of age (reporting
rate ratio = 5.9, 95% CI 1.6–22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and
death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.
© 2005 Elsevier Ltd. All rights reserved.
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1. Introduction
Yellow fever vaccine (YEL) has been used for more than
60 years. All yellow fever (YF) virus strains used for vac-
cine production are derived from the 17D strain [1]. The only
YEL licensed for use in the United States is YF-VAX®, man-
ufactured and distributed by Aventis Pasteur, Inc. Annually
in the U.S., an average of 600,000 YEL doses is distributed
to the U.S. military; another ∼300,000 doses are distributed
to travel clinics in the civilian sector (Aventis Pasteur Inc,
personal communication, 2003). In the U.S., YEL is recom-
mended for persons aged 9 months or older traveling to areas
where YF is endemic [2] and is required for military per-
sonnel depending on their duty or likelihood of deployment
to an endemic area [4]. Several countries require a certifi-
cate of vaccination from all travelers or those arriving from
YF-endemic areas [3].
Previously, YEL was believed to be one of the safest vac-
cines [1]. Since 1996, this belief has changed, when in the
U.S., the first four cases of YEL-associated viscerotropic dis-
ease (YEL-AVD) and another four cases of YEL-associated
neurotropic disease (YEL-AND) were reported [5–7]. In mid-
2001, the U.S. Centers for Disease Control and Prevention
(CDC) initiated enhanced surveillance [2,6]. Since then, two
additional unpublished cases of YEL-AVD and one report
of YEL-AND have been identified and reported to the Vac-
cine Adverse Event Reporting System (VAERS). Similar se-
rious adverse events in persons vaccinated with YEL were
described in three additional YEL-AVD case reports from
Europe [8–10]. Deaths from YEL-AVD have been reported
in Brazil [11] and Australia [12].
Advanced age (65 years and older) was previously iden-
tified as a risk factor for systemic adverse events temporally
associated with YEL [13–14]. There is some evidence that
YEL-AVD and YEL-AND also appear more frequently in
persons of advanced age [7]. The objectives of this study were
to update our understanding of these age-specific risks by: (1)
estimating reporting rates of adverse events after YEL over
time, stratified by the civilian and military populations; (2)
determining potential risk factors for serious adverse events
after YEL; (3) assessing age-adjusted reporting rates of gen-
eral YEL adverse events, YEL-AVD and YEL-AND; and (4)
comparing age-adjusted rates of adverse events after YEL to
rates for other travel-related vaccines (Hepatitis A and Ty-
phoid).
2. Methods
VAERS is a passive surveillance system for adverse events
following immunization (AEFI) operated jointly by CDC and
the U.S. Food and Drug Administration (FDA) [15]. It mon-
itors vaccine safety in the U.S. and occasionally receives re-
ports from other countries on events following administration
of U.S.-licensed vaccines. Reports of serious adverse events
[16] (see definition in Box 1) are followed up by telephone
Box 1: Code of federal regulations definition of
serious adverse events following immunization
Serious adverse event—any adverse experience, occur-
ring after administration of any vaccine dose that
results in any of the following outcomes
• Death
• Life-threatening illness
• Inpatient hospitalisation
• Prolongation of existing hospitalisation
• Persistent or significant disability
to obtain additional information about the event and the pa-
tient’s medical history. For serious YEL AEFI reports, the
follow-up is further enhanced, including presentation of case
reports to the Yellow Fever Vaccine Safety Working Group
for discussion about a possible causal relationship to vaccina-
tion. Also for any events similar to YEL-AVD or YEL-AND,
samples of serum and/or cerebrospinal fluid are requested for
YF IgM or IgG testing at CDC.
2.1. Source of cases and case classification
In this study, we included all VAERS reports of events fol-
lowing YEL vaccination during 1990–2002, in U.S. or in U.S.
citizens stationed overseas. Data were stratified by military
or civilian status. A report was classified as a military report
if the vaccine was administered at a military clinic or vaccine
was purchased with military funds. In this analysis, we cate-
gorized as “serious” all adverse events after YEL that met the
regulatory definition [16] of serious (Box 1), with the excep-
tion of hospitalized cases of anaphylactic reactions because
the risk associated with anaphylaxis has been studied earlier
[17]. Cases of anaphylaxis were included in the “non-serious”
category. Among serious reports, YEL-AVD and YEL-AND
cases were identified according to criteria described in pub-
lished case reports [5–7,18]. YEL-AVD is a term for multi-
ple organ system failure after yellow fever vaccination that
can include renal, hepatic, respiratory failure, myocarditis,
disseminated intra-vascular coagulation. YEL-AND includes
post-vaccinal encephalitis, Guillain-Barre syndrome and au-
toimmune disease with central or peripheral nervous system
involvement following YEL administration. Data were strati-
fied by age (1–18, 19–29, 30–39, 40–49, 50–59, 60–69, ≥70
years). The investigators that classified the cases were not
blinded to their age. We had information on the number of
previous YEL doses received in the past only for YEL-AVD
and YEL-AND cases.
As comparison groups for our study, we used reports after
receipt of two other common travel vaccines: typhoid vac-
cine (Typh) and hepatitis A vaccine (Hep A). For the civilian
population, we selected serious AEFI after Typh reported to
VAERS from 1997 to 2002 and after Hep A reported from
1995 to 1998, and calculated age-adjusted reporting rates.
For military reports, age-adjusted reporting rates for YEL
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were compared with those for Typh for 1998–2002 only. We
did not include Hep A data after 1999 because the Advisory
Committee for Immunization Practices (ACIP) made recom-
mendations to include Hep A in the childhood immunization
schedule [19] in areas with higher incidence of Hepatitis A.
Thus, a large proportion of doses sold was used in children,
making Hep A an inappropriate comparison to YEL. To avoid
double counting, reports that indicated that Typh or Hep A
were administered in combination with YEL were analyzed
only in the YEL group. There were a total of 360 reports
where YEL was co-administered with Typh or Hep A or with
both, Typh and Hep A.
For all analyses, we excluded foreign and duplicate re-
ports. Also excluded were three reports of co-incidental
deaths caused by pre-existing underlying illness (two deaths
were due to coronary failure secondary to coronary artery
disease and one due to multiple myeloma) and eight YEL-
reports occurring >60 days after vaccination, indicating a lack
of temporal association with vaccination.
2.2. YEL AEFI reporting rates over time
To determine reporting rates of adverse events after YEL
over time, we divided the number of YEL AEFI cases re-
ported to VAERS by the number of YEL doses distributed by
year. The annual number of YEL doses purchased by civilian
and military providers in the U.S. from 1990 to 2002, was
provided by Aventis Pasteur Inc.
2.3. Age as a risk factor
We used two strategies to examine age as a risk factor for
YEL AEFI. First, we used a logistic regression model to iden-
tify the factors associated with the YEL AEFI being reported
as serious versus non-serious. The model was controlled for
age, sex, military status, and YEL administered alone or in
combination with other vaccines.
Second, we examined age-specific reporting rates for seri-
ous AEFI following YEL and the comparison vaccines. Those
rates are a proxy for the true risk. Age-specific reporting rates
for serious and non-serious AEFI after YEL, Typh, and Hep
A were calculated by dividing the number of AEFI reported
to VAERS by the estimated number of people receiving the
vaccine in each age group. Age-specific reporting rate ra-
tios (RRR) for serious and non-serious AEFI were calculated
with a reference group of 19–29-year-old vaccine recipients.
Finally, we compared the YEL AEFI age-adjusted rates with
those for Typh and Hep A. Finding higher rates of AEFI
among age strata of recipients of YEL than among the same
age groups of recipients of the comparison vaccines may sug-
gest that YEL is associated with greater risk for some age
groups.
2.3.1. Number of vaccinated civilians, YEL
Telephone surveys with health care providers indicated
little or no wastage of YEL [13]; therefore, doses distributed
were assumed to be a reasonable estimate of the number of
persons vaccinated.
2.3.2. Number of vaccinated civilians, Typh and Hep A
Among civilians, the annual number of Typh doses dis-
tributed in the U.S., obtained from the CDC Biologics
Surveillance System (personal communication, National Im-
munization Program, 2003), and the number of Hep A
doses distributed, obtained from the manufacturers (Havrix,
SmithKline Beecham; and Vaqta, Merck & Co. Inc.), was
used to estimate the number of persons vaccinated. The num-
ber of doses sold was available for Typh for 1997–2002 and
Hep A for 1995–1998. Based on information provided by
manufacturers of Typh, it was estimated that 85% of the doses
sold were administered [21]. During this period three types of
Typh were available in the U.S.: an oral live-attenuated vac-
cine (Ty21a); a parental heat-inactivated vaccine (Typhoid
vaccine), and a parental capsular polysaccharide vaccine (Ty-
phim Vi). For Hep A, it was estimated that 10% of doses were
wasted and that 50% of vaccinees received both doses in the
series [13]. The total number of Hep A doses sold was re-
duced accordingly to estimate the total number of persons
vaccinated.
2.3.3. Age distribution of civilian vaccinees
Among civilians, the number of persons that received
YEL, Hep A or Typh vaccine in each age group was calculated
by multiplying the estimated total number of vaccine doses
administered by the proportion of persons in each age group
according to a survey of the thirteen U.S.-based GeoSentinel
travel clinics [13,20].
2.3.4. Number and age distribution of military vaccinees
Information on the number and age distribution of ac-
tive duty military personnel who received YEL and/or Typh
was obtained from the Defense Medical Surveillance System
(DMSS) for 1998–2002. DMSS is a large-linked database,
which includes military immunization registry data.
2.4. Statistical analysis
Confidence intervals (CI) for RRR were calculated based
on standard statistical assumptions for CI for ratios of rates.
Cochran-Armitage tests were conducted to examine the sig-
nificance of the trend in reporting rates over time and age-
specific reporting rates. An analysis of all YEL, Typh and Hep
A AEFI reports was conducted using SAS version 8.2 (SAS
Institute Inc., Cary, NC, USA). We used Epi-Info version 6.04
software (CDC, Stone Mountain, GA) [22] to calculate RRR
and 95% CI.
3. Results
In 1990–2002, 144,072 primary adverse event reports for
all vaccines used in the U.S. were submitted to VAERS.
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Fig. 1. Diagram of yellow fever vaccine (YEL) adverse events, 1990–2002. N, number of reports; VAERS, Vaccine Adverse Event Reporting System;
AEFI, adverse events following immunization; YEL-AVD, yellow fever vaccine-associated viscerotropic disease; YEL-AND, yellow fever vaccine-associated
neurotropic disease.
Of those, 722 (0.5%) were YEL AEFI reports that met this
study’s inclusion criteria. Of these, 65 reports were excluded
only from the age-specific rate calculation due to missing
age data. Of the 722 YEL AEFI reports, 465 (64%) were
civilian reports and 257 (36%) were military reports (Fig. 1).
Among civilian reports, 35 (8%) were categorized as seri-
ous, of which seven were grouped as YEL-AVD cases and
eight as YEL-AND cases. Among military reports, 12 (5%)
were serious, including one YEL-AVD and two YEL-AND
cases. Four deaths occurred among civilian YEL-AVD cases,
and one in the military; of the YEL-AND cases, all recovered
without sequelae. All YEL-AVD and YEL-AND cases devel-
oped in primary yellow fever vaccinees. In 190 (26%) reports,
YEL was administered alone, in 360 (50%) reports YEL was
co-administered with Typh, HepA or with both of them con-
currently along with other vaccines. In the military personnel,
anthrax, measles-mumps-rubella, tetanus-diphtheria toxoid,
influenza vaccines and many others were co-administered
with YEL.
In 1990–2002, U.S. civilian providers purchased an esti-
mated 2.2 million doses of YEL, and the military purchased
Fig. 2. Reporting rates of serious yellow fever vaccine adverse events from
the civilian and military sectors, VAERS, 1990–2002. YEL-AVD, yellow
fever vaccine-associated viscerotropic disease.
7.4 million doses. The reporting rates of serious YEL AEFI
from the civilian and military sectors significantly increased
over time (p< 0.05) (Fig. 2). Similar increases were observed
for non-serious YEL AEFI. Reporting rates were higher
among civilians for both non-serious and serious AEFI. The
reporting rate of serious AEFI was 1.6 per 100,000 doses
among civilians, and 0.2 per 100,000 doses in the military
(p< 0.05).
In the logistic regression model decennial age groups≥40
years were a significant risk factor for serious YEL AEFI
(Table 1) (adjusted odds ratios = 3.2–17.2, p< 0.05). How-
ever, receiving YEL in combination with other vaccines was
not a significant risk factor for developing a serious AEFI.
In the civilian population, in the reference age group
(19–29 years) the reporting rate for serious YEL AEFI was
Table 1
Risk factors for serious adverse events following yellow fever vaccine (YEL)
administration, 1990–2002
Risk factor N (%)
(serious)
N (%)
(non-serious)
AOR† (95% CI)
YEL administered
YEL alone 15 (32%) 175 (26%) 1.4 (0.7–2.7)
YEL with other
vaccines
32 (68%) 500 (74%) Ref
Military status
Yes 12 (26%) 245 (36%) 1.4 (0.6–3.1)
No 35 (74%) 430 (64%) Ref
Gender
Male 25 (54%) 358 (54%) (0.6–2.0)
Female 21 (46%) 303 (46%) Ref
Age group (years)
1–18 4 (8%) 78 (13%) 1.1 (0.3–3.8)
19–29 6 (13%) 205 (34%) Ref
30–39 7 (15%) 135 (22%) 1.8 (0.6–5.7)
40–49 8 (17%) 92 (15%) 3.2 (1.1–9.8)
50–59 7 (15%) 57 (9%) 4.1 (1.2–14.1)
60–69 8 (17%) 27 (4%) 12.2 (3.6–41.7)
≥70 7 (15%) 16 (3%) 17.2 (4.7–63.0)
CI, confidence intervals; Ref, reference group; AOR†, adjusted odds ratio,
logistic regression model.
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Fig. 3. Reporting rates of serious adverse events (AE) after yellow fever
(CIV YEL, 1990–2002), Typhoid (CIV TYPH, 1997–2002) and Hepatitis
A (CIV Hep A, 1995–1998) vaccines in U.S. civilians and military (MIL
YEL, 1998–2002). CIV, civilian; MIL, military; YEL, yellow fever vaccine;
TYPH, typhoid vaccine; Hep A, hepatitis A vaccine.
0.7 per 100,000 doses (Table 2), and it increased significantly
for persons ≥60 years of age (p< 0.0001). Overall, among
civilian vaccinees aged ≥60 years, the estimated reporting
rate of serious AEFI was 5.3 per 100,000 vaccinations, risk
of YEL-AVD was 1.8 per 100,000 and of YEL-AND 1.4 per
100,000 vaccinations. Compared with the reference group,
the reporting rate ratio (RRR) for serious AEFI for those
60–69 years of age was 5.9 (95% CI 1.6–22.2); for those
≥70 years of age, it was 10.4 (95% CI 2.7–40.2). The results
remained significant when only reports of AEFI after YEL
administered alone were analyzed. When the analysis was
restricted to vaccinees that developed YEL-AVD or YEL-
AND, the pattern was similar to the RRR for serious YEL
AEFI (Table 2). Compared with the reference group, the RRR
for YEL-AVD for those 60–69 years of age was 4.4 (95% CI
0.4–48.7); for those ≥70 years of age, it was 13.4 (95% CI
1.4–128.5). There was an increase in RRR for YEL-AND in
age groups 60–69 years and ≥70 years of age but it was not
significant (p> 0.05) (Table 2).
In the military population, the age-specific reporting rates
for serious YEL AEFI were similar to those in civilians
(Table 3). There were no serious YEL AEFI reports for per-
sons ≥50 years of age. There was no trend of serious AEFI
reporting rates with increasing age (p> 0.1) (Fig. 3).
From 1995 to 1998, it was estimated that 3.2 million doses
of Hep A were administered in the civilian population, and
44 serious AEFI reports were submitted to VAERS. The re-
porting rate for serious AEFI in vaccinees 60–69 years of age
was 2.8 per 100,000 persons vaccinated. However, there was
no significant consistent increase in the reporting rate of se-
rious AEFI for older age groups (p> 0.05) as found for YEL
(Fig. 3).
From 1997 to 2002, an estimated 3.2 million Typh doses
were administered among civilians. Of all the Typh AEFI re-
ports, 63% were after Typhim Vi, 16% after Ty21a, 7% after
whole cell Typhoid vaccine and 14% with unknown manufac-
turer. During that period, 21 serious Typh AEFI reports were
submitted to VAERS. The reporting rate for serious AEFI in
those 60–69 years of age was 0.8 per 100,000. As with Hep Ta
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Table 3
Reporting rates and reporting rate ratios for yellow fever and typhoid vaccine
adverse events by age in the U.S. military, 1998–2002
Age (years) Number of
doses
Number of
Ser AEFIa
Ser AEFIa re-
ports/100,000
doses
RRRb (95% CI)
Yellow fever vaccine
17–18 148776 1 0.7 1.8 (0.2–19.3)
19–29 519908 2 0.4 Ref
30–39 185765 3 1.6 4.2 (0.7–25.1)
40–49 58984 1 1.7 4.4 (0.4–48.6)
≥50 13552 0 0 0
Total 926985 7 0.8
Typhoid vaccine
17–18 78916 1 1.3 4.3 (0.4–40.9)
19–29 1007770 3 0.3 Ref
30–39 498458 4 0.8 2.7 (0.6–12.0)
40–49 164567 1 0.6 2.0 (0.2–19.6)
≥50 38154 1 2.6 8.8 (0.9–84.6)
Total 1787865 10 0.6
CI, confidence intervals; Ref, reference.
a Ser AEFI, serious adverse events following immunization.
b RRR, reporting rate ratio.
A, there was no significant increase for serious Typh AEFI
for each older age group (p> 0.1), and although recipients
≥70 years of age had a higher reporting rate, it was not sig-
nificantly different from those aged 19–29 years (RRR = 2.0,
95% CI 0.4–10.3) (Fig. 3). There was no significant increase
in reporting rates of serious AEFI after Typh by age in the
military (p> 0.1) (Table 3).
4. Discussion
Next to smallpox vaccine, YEL has been in use the longest
among the live viral vaccines. While YEL had the reputation
of being extremely safe [1], its safety profile now needs to be
updated. Two serious and frequently fatal AEFIs mimicking
wild YF disease, YEL-AVD and YEL-AND, have been newly
recognized as clinical entities [5–7,11,18]. In this extended
U.S. study based on 12 years of VAERS data, we confirmed
that the relative risks of serious YEL AEFI are higher in per-
sons of advanced age. We used YEL AEFI data from civilians
and, for the first time, military service members’ reports. In
addition, we were able to estimate the minimal risk of YEL-
AVD and YEL-AND based on passive surveillance.
We determined that advanced age is a risk factor for seri-
ous YEL AEFI from multiple lines of evidence. Using logis-
tic regression, we found an increase in the reporting rate of
serious YEL AEFI in all age groups ≥40 years, with a sig-
nificant increase in reporting rates in persons ≥60 years of
age. In the civilian population, using age-adjusted reporting
rate calculations, we also identified a significant increase in
the rate of serious YEL AEFI in persons aged≥60 years and
of YEL-AVD in those ≥70 years of age. The reporting rates
of YEL-AND also increased for persons aged ≥60 years, al-
though not significantly. In the military, we were not able to
see the effect of advanced age on serious YEL AEFI because
the age of its population is typically 17–50 years.
In contrast, no significant increases in reporting rates of
serious AEFI in older age groups were found for two other
travel vaccines, Hep A and Typh. This suggests that the higher
reporting rate of serious YEL AEFI in persons of advanced
age is real and not an artifact associated with passive surveil-
lance. The increased rate of serious YEL AEFI is biologically
plausible, as there is an increased risk of developing serious
illness in persons of older age after the wild YF virus infection
[23].
During 1990–2002, overall YEL AEFI reporting rates to
VAERS increased both in the civilian and military popula-
tions. The reporting patterns of AEFI from the military are
different from those in the civilian sector. Until 1999, YEL
AEFI reports submitted from the military tended to include
primarily serious reports, because the regulations [4] that
mandated reporting of AEFI [16] did not emphasize report-
ing of non-serious events. The increase in reporting rates in
the military corresponds to the changes in policy of reporting
AEFI related to the use of anthrax vaccine, when all AEFI
were encouraged to be reported to VAERS [24].
The military reporting rates over time are underestimates
due to the large difference between doses purchased and ad-
ministered. For calculation of these rates, we used denomina-
tor provided by the vaccine manufacturer. However, for the
last 4 years, we saw the difference between these data and
immunizations received that were captured in DMSS. The re-
porting rates of serious AEFI in the military for the age 17–49
years are comparable with those in civilian population in the
same age deciles. The data presented in Tables 2 and 3 and
Fig. 3, support the presence of age confounding in the mil-
itary. More than 98% of military vaccinations occur among
persons aged <50 years, the point at which the reporting rates
for serious YEL AEFI in the civilian population begin to in-
crease significantly. The military purchases more YEL doses,
but the total number of AEFI reports and overall reporting
rates for YEL are lower than in the civilian sector. However,
it is still a substantial contribution to YEL AEFI reporting.
This study has several limitations. First, VAERS has
methodological limitations inherent to passive surveillance
systems, such as underreporting, incomplete reporting and
lack of consistent diagnostic criteria [25]. Thus, the estimates
of events obtained from VAERS may underestimate the true
rates of serious YEL AEFI. Second, using other sources to
obtain an overall number of persons vaccinated may lower
the risk estimates. The number of people receiving vaccine
in the military was obtained from DMSS. However, it may
under-represent some of the branches (e.g., Navy and Army)
due to the differences in reporting to DMSS. For civilians, we
used doses sold as an estimate for doses administered, which
is likely to be an overestimate. Third, the 1998 GeoSentinel
survey [13], used to estimate the number of doses of vaccine
administered in each age group, has the following limitations:
children might have been underrepresented and the age distri-
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bution of travelers receiving YEL could have changed over
time. The number of elderly travelers may have increased,
since 1998. If this is true, then we might have overestimated
the RRR for the elderly.
Our study emphasizes the need for travelers and physicians
to be educated on the risks and benefits of YEL vaccinations.
The CDC has developed a yellow fever vaccine information
sheet. The FDA and the U.S. vaccine manufacturer have re-
vised the package insert to caution yellow fever vaccination
of older age groups [26]. The majority of the YEL-AVD and
YEL-AND cases have been published in the scientific lit-
erature [5–7]. Most challenging, however, is the continual
need to better educate physicians to weigh the risks and ben-
efits of YEL vaccination in older travelers. In doing so, there
are five basic actions: assessing baseline health, reviewing
intended journey itinerary, assessing disease exposure risk,
deciding upon and administering vaccines, and educating on
disease prevention and health maintenance [27]. Health care
providers may wish to consider a medical waiver for those
travelers who have contraindications to yellow fever vaccine
but require documentation of vaccination for entry purposes.
The true risk of getting YF disease for a traveler is un-
known and depends on the country, area in the country, sea-
son and YF virus activity. An estimate of the risk of getting
YF illness for unvaccinated traveler to YF-endemic areas in
Africa is 1/4,200 (23.8 per 100,000 per week) and 1/280 (357
per 100,000 per week) for YF epidemic areas in Africa [28].
These estimates are based on research in indigenous popula-
tions and might overestimate the risk of illness in a traveler.
Based on data from U.S. travelers, the risk of YF disease in
a traveler has been estimated to be 0.4–4.3 cases per million
travelers to YF-endemic countries [3]. Unfortunately, in our
study, we likely underestimate the true risk of serious YEL
AEFI due to underreporting inherent in passive surveillance.
Nevertheless, these data suggest this risk is≥1.6 per 100,000
vaccinations, the risk of developing YEL-AVD or YEL-AND
are ≥0.3 per 100,000. In vaccinees ≥60 years of age, the
risk of serious AEFI increases to ≥5.3 per 100,000 and of
YEL-AVD ≥1.8 per 100,000 vaccinations. All the cases of
YEL-AVD and YEL-AND reported to this date occurred in
primary yellow fever vaccinees. Although the true risk for
travelers is unknown, YEL is beneficial for prevention of YF
disease with a mortality rate of 20–50% [28]. It is critical to
emphasize that this risk-benefit analysis is limited to travelers
moving from low or no risk areas to YF-endemic or epidemic
areas and does not apply to natives living in areas of YF trans-
mission for whom the benefits of YEL clearly outweigh the
risks. However, for individuals, especially older persons, it
is important to weigh the potential risk of developing sys-
temic illness after YEL and the choice of making a trip to
YF-endemic area.
YF is a serious and potentially fatal disease. YEL vaccine
is highly efficacious and rarely causes serious AEFI [1–2].
There is a need to continue to vaccinate travelers that are go-
ing to YF-endemic areas. The data from this study emphasize
the importance of carefully screening travel itineraries, par-
ticularly of older travelers, and vaccinating only those trav-
eling to YF-endemic or epidemic areas.
Physicians should work with travelers to ensure that they
understand the risk and benefit of YEL vaccination. Travel-
ers who opt against vaccination need to be counseled thor-
oughly by their physician on alternative precautions (e.g., use
of DEET, bed nets, appropriate clothing) to prevent mosquito
bites. Further studies are underway in the U.S. to improve the
estimate of the true risk of serious and systemic YEL AEFI.
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